糖工程化细菌膜囊泡疫苗经黏膜初免-系统加强诱导抗肺炎链球菌保护性黏膜免疫
本研究用展示肺炎链球菌荚膜多糖的糖工程化益生菌大肠杆菌膜囊泡疫苗,在小鼠中评估八种三剂次鼻内和皮下免疫组合。结果显示所有方案均诱导体液免疫,仅IN-IN-IN、IN-IN-SC和SC-IN-IN诱导强黏膜SIgA并增强鼻腔清除,其中IN-IN-SC方案黏膜与系统免疫最平衡且调理吞噬活性最高,支持途径优化。
要点
- 糖工程化膜囊泡疫苗经不同途径均诱导血清IgG。
- 黏膜SIgA和鼻腔清除仅见IN-IN-IN、IN-IN-SC、SC-IN-IN。
- IN-IN-SC方案黏膜系统免疫最平衡,调理吞噬活性最高。
核心结论
- 黏膜初免-系统加强(IN-IN-SC)方案可平衡黏膜与系统免疫并增强肺炎链球菌清除。
- 疫苗经不同途径均有免疫原性,但途径组合决定黏膜SIgA和清除效果。
研究设计与样本
- 研究评估八种三剂次IN和SC免疫组合,疫苗为展示肺炎链球菌荚膜多糖的糖工程化益生菌大肠杆菌膜囊泡。
主要发现
- 所有免疫方案均诱导血清IgG应答。
- 仅IN-IN-IN、IN-IN-SC和SC-IN-IN诱导强黏膜SIgA并增强鼻腔肺炎链球菌清除。
- IN-IN-SC方案黏膜与系统免疫最平衡且调理吞噬活性最高。
关键数值与推荐
- 有效黏膜SIgA和鼻腔清除见于IN-IN-IN、IN-IN-SC和SC-IN-IN方案。
- 调理吞噬活性最高者为IN-IN-SC方案。
临床怎么用
- 提示黏膜初免-系统加强策略可作为优化糖工程化膜囊泡疫苗免疫效果的实用途径。
- 在疫苗开发中应重视免疫途径组合对黏膜免疫和清除能力的决定作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Prime-boost vaccination using different administration routes may enhance protective immunity compared with homologous regimens. Here, we evaluated all eight possible three-dose combinations of intranasal (IN) and subcutaneous (SC) immunization using a glycoengineered membrane vesicle vaccine derived from probiotic Escherichia coli and displaying pneumococcal capsular polysaccharide. This self-adjuvanting vaccine platform induced robust humoral responses regardless of administration route. While all regimens elicited serum IgG responses, only IN-IN-IN, IN-IN-SC, and SC-IN-IN induced strong mucosal SIgA responses and enhanced pneumococcal clearance in the nasal cavity. Among these, the heterologous IN-IN-SC regimen generated the balanced mucosal and systemic immunity and exhibited the highest opsonophagocytic activity. These findings support route optimization as a practical strategy for maximizing the efficacy of glycoengineered membrane vesicle vaccines.
引用
- Nakao R, Uchiyama H, Yamaguchi T, et al. A mucosal prime-systemic boost strategy using a glycoengineered bacterial membrane vesicle vaccine elicits protective mucosal immunity against pneumococci in mice. Vaccine. 2026. PMID: 42759251. doi:10.1016/j.vaccine.2026.129142
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。